Citadel Advisors
VERV

Citadel Advisors’s Verve Therapeutics VERV Stock Holding History

Citadel Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-115,600
Closed -$1.3M – 14204
2025
Q2 		$1.3M Buy
115,600
+103,900
+888% +$592K ﹤0.01% 6539
2025
Q1 		$53.5K Sell
11,700
-2,800
-19% -$18.8K ﹤0.01% 12246
2024
Q4 		$81.8K Buy
14,500
+7,000
+93% +$39.5K ﹤0.01% 11759
2024
Q3 		$36.3K Sell
7,500
-4,900
-40% -$28.5K ﹤0.01% 12253
2024
Q2 		$60.5K Sell
12,400
-25,400
-67% -$160K ﹤0.01% 11556
2024
Q1 		$502K Sell
37,800
-6,100
-14% -$80.9K ﹤0.01% 8397
2023
Q4 		$612K Buy
43,900
+12,100
+38% +$150K ﹤0.01% 7664
2023
Q3 		$422K Buy
31,800
+26,700
+524% +$430K ﹤0.01% 8438
2023
Q2 		$95.6K Sell
5,100
-1,100
-18% -$18.3K ﹤0.01% 11010
2023
Q1 		$89.4K Sell
6,200
-105,800
-94% -$2.07M ﹤0.01% 11423
2022
Q4 		$2.17M Sell
112,000
-27,900
-20% -$739K ﹤0.01% 5318
2022
Q3 		$4.81M Buy
139,900
+3,100
+2% +$98.9K ﹤0.01% 3939
2022
Q2 		$2.09M Buy
136,800
+127,900
+1,437% +$1.98M ﹤0.01% 5456
2022
Q1 		$203K Sell
8,900
-3,900
-30% -$111K ﹤0.01% 11505
2021
Q4 		$472K Buy
+12,800
New +$538K ﹤0.01% 9849

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's VERV Position: Q3 2025 in Review

Citadel Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 288,004 shares — an estimated $3.23M sold.

Citadel Advisors first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $48.7M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Citadel Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 288,004 Verve Therapeutics shares in Q3 2025, an estimated $3.23M.
  • Citadel Advisors first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Citadel Advisors's Verve Therapeutics position peaked at $48.7M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.